Expedia, Citigroup, Target: New Ratings
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
STOCK COMMENTS / EPS CHANGES
(ADS - Get Report) target boosted at RBC. Shares of ADS now seen reaching $96, according to RBC. Company should reach it's near-term earnings targets. Outperform rating.
(AMSG - Get Report)
price target boosted at Citi to $32.50 from $24. Bullish on acquisition of Dallas based National Surgical Care, Citigroup said. Maintain Buy rating.
estimates, target upped at UBS. STZ estimates were boosted through 2013, UBS said. Company is realizing higher shipments. Buy rating and new $25 price target.
estimates reduced at Goldman through 2013, Goldman Sachs said. Company is realizing a lower Medicare reimbursement. Neutral rating and $46 price target.
(IMAX - Get Report)
target raised at Piper. Shares of IMAX now seen reaching $37. Company is expanding its reach across the globe. Overweight rating.
numbers upped at Piper. JCP estimates were boosted through 2012, Piper Jaffray said. Company is realizing higher sales. Neutral rating and new $32 price target.
target boosted at Morgan Stanley. Shares of LTD now seen reaching $41, according to Morgan Stanley. Company is posting double-digit sales growth. Overweight rating.
(PCLN - Get Report)
estimates, target raised at Goldman. Shares of PCLN now seen reaching $600, according to Goldman Sachs. Estimates also increased, given expected growth in Europe. Buy rating.
estimates lowered at Goldman through 2012, Goldman Sachs said. Company is spending more on domestic marketing. Buy rating and $77 price target.
(PFE - Get Report)
price target raised at Credit Suisse to $23 from $21. Value exists in the case of a Pfizer Animal Health spin-off, Credit Suisse said. Maintain Outperform rating.
Pier 1 Imports
(PIR - Get Report)
price target higher at Credit Suisse. PIR shares now seen reaching $13, up from $11. Strong comps reinforce solid long-term growth, Credit Suisse said. Maintain Neutral rating.
(STX - Get Report)
numbers increased at Goldman through 2013, Goldman Sachs said. Company is realizing higher margins. Neutral rating and new $16 price target.
price target reduced at Goldman to $60, according to Goldman Sachs. Cinoany is seeing weaker sales. Buy rating.